289 related articles for article (PubMed ID: 16322991)
61. Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment.
Lathia C; Fleming GF; Meyer M; Ratain MJ; Whitfield L
Cancer Chemother Pharmacol; 2002 Aug; 50(2):121-6. PubMed ID: 12172976
[TBL] [Abstract][Full Text] [Related]
62. Use of pemetrexed in breast cancer.
Dittrich C
Semin Oncol; 2006 Jun; 33(3 Suppl 9):S24-8. PubMed ID: 16797379
[TBL] [Abstract][Full Text] [Related]
63. Population pharmacokinetics of high-dose carboplatin in children and adults.
Lindauer A; Eickhoff C; Kloft C; Jaehde U
Ther Drug Monit; 2010 Apr; 32(2):159-68. PubMed ID: 20110851
[TBL] [Abstract][Full Text] [Related]
64. A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer.
Garin A; Manikhas A; Biakhov M; Chezhin M; Ivanchenko T; Krejcy K; Karaseva V; Tjulandin S
Breast Cancer Res Treat; 2008 Jul; 110(2):309-15. PubMed ID: 17851759
[TBL] [Abstract][Full Text] [Related]
65. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer.
Socinski MA; Weissman C; Hart LL; Beck JT; Choksi JK; Hanson JP; Prager D; Monberg MJ; Ye Z; Obasaju CK
J Clin Oncol; 2006 Oct; 24(30):4840-7. PubMed ID: 17050869
[TBL] [Abstract][Full Text] [Related]
66. Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients.
Urien S; Brain E; Bugat R; Pivot X; Lochon I; Van ML; Vauzelle F; Lokiec F
Cancer Chemother Pharmacol; 2005 Jan; 55(1):55-60. PubMed ID: 15258698
[TBL] [Abstract][Full Text] [Related]
67. Population pharmacokinetics of oral busulfan in children.
Schiltmeyer B; Klingebiel T; Schwab M; Mürdter TE; Ritter CA; Jenke A; Ehninger G; Gruhn B; Würthwein G; Boos J; Hempel G
Cancer Chemother Pharmacol; 2003 Sep; 52(3):209-16. PubMed ID: 12811512
[TBL] [Abstract][Full Text] [Related]
68. Pharmacokinetics of fluconazole in people with HIV infection: a population analysis.
McLachlan AJ; Tett SE
Br J Clin Pharmacol; 1996 Apr; 41(4):291-8. PubMed ID: 8730974
[TBL] [Abstract][Full Text] [Related]
69. Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies.
Chen X; Bies RR; Ramanathan RK; Zuhowski EG; Trump DL; Egorin MJ
Cancer Chemother Pharmacol; 2005 Mar; 55(3):237-43. PubMed ID: 15503027
[TBL] [Abstract][Full Text] [Related]
70. Population pharmacokinetics of PM00104 (Zalypsis(®)) in cancer patients.
Pérez-Ruixo C; Valenzuela B; Fernández Teruel C; González-Sales M; Miguel-Lillo B; Soto-Matos A; Pérez-Ruixo JJ
Cancer Chemother Pharmacol; 2012 Jan; 69(1):15-24. PubMed ID: 21590449
[TBL] [Abstract][Full Text] [Related]
71. Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation.
Lowis SP; Pearson AD; Newell DR; Cole M
Cancer Res; 1993 Oct; 53(20):4881-9. PubMed ID: 8402676
[TBL] [Abstract][Full Text] [Related]
72. A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors.
Dy GK; Suri A; Reid JM; Sloan JA; Pitot HC; Alberts SR; Goldberg RM; Atherton PJ; Hanson LJ; Burch PA; Rubin J; Erlichman C; Adjei AA
Cancer Chemother Pharmacol; 2005 Jun; 55(6):522-30. PubMed ID: 15754203
[TBL] [Abstract][Full Text] [Related]
73. High dose methotrexate population pharmacokinetics and Bayesian estimation in patients with lymphoid malignancy.
Min Y; Qiang F; Peng L; Zhu Z
Biopharm Drug Dispos; 2009 Nov; 30(8):437-47. PubMed ID: 19746402
[TBL] [Abstract][Full Text] [Related]
74. Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation.
Rinaldi DA; Burris HA; Dorr FA; Woodworth JR; Kuhn JG; Eckardt JR; Rodriguez G; Corso SW; Fields SM; Langley C
J Clin Oncol; 1995 Nov; 13(11):2842-50. PubMed ID: 7595747
[TBL] [Abstract][Full Text] [Related]
75. [Pemetrexed nephrotoxicity].
Izzedine H
Bull Cancer; 2015 Feb; 102(2):190-7. PubMed ID: 25641712
[TBL] [Abstract][Full Text] [Related]
76. A phase I/II study of neoadjuvant chemotherapy with Pemetrexed (Alimta) in rectal cancer.
Derwinger K; Kodeda K; Swartling T; Kälebo P; Carlsson G; Gustavsson B
Eur J Surg Oncol; 2011 Jul; 37(7):583-8. PubMed ID: 21550200
[TBL] [Abstract][Full Text] [Related]
77. Pemetrexed (Alimta): a promising new agent for the treatment of breast cancer.
Calvert H
Semin Oncol; 2003 Apr; 30(2 Suppl 3):2-5. PubMed ID: 12722017
[TBL] [Abstract][Full Text] [Related]
78. Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia.
Petersen KB; Jusko WJ; Rasmussen M; Schmiegelow K
Cancer Chemother Pharmacol; 2003 Jun; 51(6):465-73. PubMed ID: 12698270
[TBL] [Abstract][Full Text] [Related]
79. Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer.
Takimoto CH; Hammond-Thelin LA; Latz JE; Forero L; Beeram M; Forouzesh B; de Bono J; Tolcher AW; Patnaik A; Monroe P; Wood L; Schneck KB; Clark R; Rowinsky EK
Clin Cancer Res; 2007 May; 13(9):2675-83. PubMed ID: 17473199
[TBL] [Abstract][Full Text] [Related]
80. Overview of phase I trials of multitargeted antifolate (MTA, LY231514).
Rinaldi DA
Semin Oncol; 1999 Apr; 26(2 Suppl 6):82-8. PubMed ID: 10598560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]